Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: Drs Alfonso and Sabate identify that the irradiated segment was longer than the segment covered by sirolimus-eluting stents in the SISR trial. This discrepancy in length was in part related to the specific concern raised about geographic miss. The operators in the trial attempted to minimize this problem by fully covering the margins with radiation. The standard recommended vascular brachytherapy practice during this time was to extend the radiation treatment to 5 mm beyond the injured margins.
Holmes DR. Sirolimus-Eluting Stents vs Brachytherapy for Restenosis—Reply. JAMA. 2006;296(15):1837-1838. doi:10.1001/jama.296.15.1838-a